Czech Working Group for Ph-negative @entity66 (CZEMP) recommends anagrelid (Thromboreductin  ) for the treatment of Ph-negative @entity102 (MPO) with @entity1148 accompanying. To evaluate the efficacy of this treatment, the @entity1 registry with essential @entity1148 and/or @entity1148 accompanying other @entity66 was established. The beginnings of data collection go back to 2001, registry itself is maintained from 2005 and the aim is to archive the medical records with detailed physical and laboratory examination, safety @entity1 profile included. The longest follow-up monitors 150 months period. Registry database contained 1,325 @entity1 in the end of 2013, with an annual increase of anagrelid therapy as a drug of first choice in accordance with CZEMP guidelines approved by the Czech Society of Hematology of Czech Medical Association of J. E. Purkyne. Indication criteria contribute to this trend as anagrelid is the first choice agent in 65 years old @entity1 , instead previous 60 years of age. Often, we can observe the combined treatment, especially, in older @entity1 and in @entity1 with primary @entity4018 and @entity6582 vera. There have been founded 543 @entity715 events in 413 @entity1 and 63 @entity548 events in 58 @entity1 of study group by the end of 2013. During treatment, @entity715 was diagnosed 225 times in 171 @entity1 and @entity548 was observed 139 times in 104 @entity1 . The therapeutic response is achieved after 3 months in 77% and after 6 months in 83% of subjects, but after 12 months, the treatment still fails in 12,5% of @entity1 . It might be caused by slow titration of Thromboreductin  . One of the most important indicators of treatment success is the effect on clinical symptoms presentation, especially the occurrence of @entity715 events. The proof of a good treatment efficacy is demonstrated by 1.8 fold decrease in arterial @entity715 , more than 1.5 fold decrease in microvascular @entity715 and even 6.2 fold @entity1211 events. Bleeding is observed in about double more @entity1 in comparison to the period before inclusion in the systematic monitoring, but the bleedings are clinically insignificant.Key words: anagrelid (Thromboreductin  ) - Ph- @entity66 - registry - @entity715 .

[ @entity66 with XXXX in the context of Thromboreductin   treatment, data from registry 2013].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6582 :: ('MESH:D011086', 'Disease') :: ['polycythemia'] @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocythemia', 'thrombocytosis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Ph-negative myeloproliferative diseases', 'myeloproliferative diseases', 'Myeloproliferative diseases'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic myeloproliferative disease'] @entity4018 :: ('MESH:D055728', 'Disease') :: ['myelofibrosis'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['decrease in venous thromboembolism']
@entity1148 :: (MESH:D013922,Disease) :: ['thrombocythemia']
